GleamWall
中文EN

IRD Opus Genetics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1228627 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-45.9%
TTM net income YoY-100.4%
TTM EPS YoY20.4%
Revenue 3-yr CAGR-48.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-777.7%
Net margin-1,726.7%
FCF margin—
EBITDA margin-776.9%

Returns

ROE-615.6%
ROA-208.0%
ROIC (approx.)—
Asset turnover0.12x

Leverage & solvency

Liabilities / assets59.7%
Debt / equity0.93x
Current ratio9.65x
Interest coverage-217.47x

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-134.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$14.20M$10.99M
R&D expense$30.81M$26.85M
SG&A expense$21.98M$18.21M
Operating income-$38.60M-$62.07M
Interest expense$129,000$0
Pretax income-$49.59M-$57.53M
Income tax$0$0
Net income-$49.59M-$57.53M
EBITDA-$38.55M-$62.06M
EPS (basic)-0.80-2.15
EPS (diluted)-0.80-2.15
Weighted avg. shares (diluted)62.22M26.72M
Balance sheet
Cash & equivalents$45.09M$30.32M
Short-term investments$0$2,000
Receivables$2.00M$3.56M
Current assets$50.04M$36.61M
PP&E, net$199,000$252,000
Total assets$50.24M$36.86M
Current liabilities$7.78M$11.29M
Long-term debt$1.13M$0
Total debt$1.13M$0
Total liabilities$34.90M$11.29M
Shareholders' equity$15.35M$6.72M
Net debt-$43.96M-$30.32M
Shares outstanding69.89M31.57M
Cash flow statement
Operating cash flow-$35.25M-$25.58M
Investing cash flow$0$1.21M
Financing cash flow$50.02M$4.19M
Depreciation & amortization$53,000$10,000
Stock-based compensation$3.40M$3.36M

Free plan shows the latest 2 periods; Pro shows all 24 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.